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Abstract
Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide. Inflammatory activity within the stroma of
invasive colorectal tumours is known to be a key predictor of disease activity with type, density and location of immune
cells impacting on patient prognosis. To date, there has been no report of inflammatory phenotype within pre-malignant
human colonic adenomas. Assessing the stromal microenvironment and particularly, inflammatory activity within colorectal
neoplastic lesions is central to understanding early colorectal carcinogenesis. Inflammatory cell infiltrate was assessed by
immunohistochemistry in paired colonic adenoma and adjacent normal colonic mucosa samples, and adenomas exhibiting
increasing degrees of epithelial cell dysplasia. Macrophage phenotype was assessed using double stain immunohisto-
chemistry incorporating expression of an intracellular enzyme of function. A targeted array of inflammatory cytokine and
receptor genes, validated by RT-PCR, was used to assess inflammatory gene expression. Inflammatory cell infiltrates are a
key feature of sporadic adenomatous colonic polyps with increased macrophage, neutrophil and T cell (specifically helper
and activated subsets) infiltration in adenomatous colonic polyps, that increases in association with characteristics of high
malignant potential, namely, increasing degree of cell dysplasia and adenoma size. Macrophages within adenomas express
iNOS, suggestive of a pro-inflammatory phenotype. Several inflammatory cytokine genes (CXCL1, CXCL2, CXCL3, CCL20, IL8,
CCL23, CCL19, CCL21, CCL5) are dysregulated in adenomas. This study has provided evidence of increased inflammation
within pre-malignant colonic adenomas. This may allow potential mechanistic pathways in the initiation and promotion of
early colorectal carcinogenesis to be identified.
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Introduction
Colorectal cancer (CRC) is a major health burden causing
significant morbidity and mortality, with over a million cases
diagnosed each year worldwide [1]. The majority of CRC is
sporadic, that is, associated with no identifiable heritable genetic
mutation. The accepted pathogenetic framework for this malig-
nancy is the adenoma-carcinoma sequence [2]. In understanding
pathogenesis of malignancy, the emphasis has previously rested on
epithelial cell behaviour, but over the last decade, the focus has
moved to the microenvironment as a whole and the importance of
stromal cell and epithelial cell interaction is now widely recognised
[3,4]. Inflammatory activity within the stroma of invasive
colorectal tumours is known to be a key predictor of disease
activity with type, density and location of immune cells impacting
on patient prognosis [5]. The point at which this inflammatory
infiltrate exerts influence on colorectal carcinogenesis is unknown.
In breast cancer models, non-invasive tumour cells have been
shown to recruit macrophages which induce angiogenesis and
promote malignant transformation [6]. To date, there has been no
report of inflammatory phenotype within pre-malignant human
colonic adenomas. Assessing the stromal microenvironment and
particularly, inflammatory activity within colorectal neoplastic
lesions is central to understanding early colorectal carcinogenesis,
and in particular, understanding the mechanisms involved in the
transition of pre-invasive to invasive disease. The aim of this paper
therefore was to define the inflammatory microenvironment
within pre-malignant human adenomatous colonic polyps, and
to investigate how this changes along with adenoma characteristics
linked to high malignant potential.
Materials and Methods
Assessment of inflammatory cell phenotype
Inflammatory cell phenotype was assessed by immunohisto-
chemistry on 65 colonic adenomatous polyps and 36 adjacent
normal mucosal biopsies, obtained from 36 patients at CRC
screening colonoscopy, as described previously [7]. The polyp
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sample set was expanded to include 40 colonic adenomas
exhibiting low grade dysplasia (LGD), 40 with high grade dysplasia
(HGD) and 40 adenomatous polyps with supervening invasive
adenocarcinoma (cancer polyps (CaP)) [7]. Each specimen was
evaluated to confirm histological diagnosis by an experienced
consultant gastrointestinal pathologist (GIM). The macroscopic
size of each polyp was measured post fixation, providing a
consistent measurement of size for all samples. Within the
prospectively collected polyp set, 36 were small (#1cm) and 29
large (.1cm). There was no statistically significant difference in
size distribution between the 40 LGD polyps, 40 HGD polyps or
the 40 CaP (LGD vs. HGD, p = 0.548; HGD vs. CaP, p = 0.397;
LGD vs. CaP, p = 0.068). Tissue was stained using the
Envision+TM biotin free system [8] incorporating either the
Envision+TM peroxidase linked biotin free system (Dako, K5007)
or CSA II biotin-free tyramide signal amplification (Dako, K1497),
dependant on antibody requirements (Table 1). Primary antibody
was applied for 60 minutes following antigen retrieval (Table 1).
Colour was developed with diaminobenzidine (DAB). One micro-
scopic high powered field (HPF) from each sample was digitally
imaged (640 magnification) by a gastrointestinal pathologist
(GIM) as representative of tissue type, distinct from lymphoid
aggregation and within the area of most positive staining. The
number of positive cells was counted to give a score of inflam-
matory cellular infiltrate.
Assessment of macrophage phenotype
Macrophage phenotype was assessed in 42 adenomatous polyps
and 25 adjacent normal mucosal biopsies (randomly selected
from the larger prospectively collected sample set) and polyps of
increasing epithelial cell dysplasia, as described above. A double
stain immunohistochemical technique was used, incorporating
detection of an intracellular enzymatic marker of macrophage
function, namely iNOS (pro-inflammatory classically activated
macrophage) or arginase I (alternatively activated macrophage)
[9,10](Table 1), identified by peroxidase linked immunoreactivity.
Sequential staining with CD68 detected macrophage infiltrate
using an alkaline phosphatase linked detection signal. Staining was
performed using either the G2 doublestain EnvisionTM kit or
EnvisionTM doublestain kit, dependant on supplier availability
(Dako, K5361 & K1395, respectively). Heat induced antigen
retrieval was performed. Levamisole was added to the liquid
permanent red chromagen to suppress endogenous alkaline
phosphatase activity. Optimisation ensured no cross-reactivity or
quenching of signal. The area of most positive macrophage
infiltration within one HPF (640 magnification), distinct from
lymphoid aggregation, was identified under fluorescent light at
580 nm using a Texas red filter set and digitally imaged, and also
captured under standard optical light. In relation to degree of cell
dysplasia, the area of defined histological abnormality was marked
and digitally imaged. The 2 images were imported into Corel-
Paint X3, version 13 and macrophage infiltrate assessed for
expression of either iNOS or arginase I.
Profiling inflammatory gene expression
Tissue representative of each stage of the adenoma-carcinoma
sequence (normal mucosa, adenoma and adenocarcinoma) was
obtained from 7 colectomy specimens as part of an ongoing CRC
tissue specimen bank, as previously published [11]. Histological
analysis confirmed pathological diagnosis. RNA was extracted
Table 1. Characteristics of the antibodies used for the immunohistochemical analysis of inflammatory cell infiltrate.
Inflammatory
cell type
Inflammatory
cell marker Type
Antigen
retrieval
method*
Positive tissue
control Dilution
IHC detection
protocol Supplier Code
Isotype/
Clone
T helper cell CD4 mouse
monoclonal
M20-high
pH
Tonsil 1:100 Envision Novocastra NCL-CD4-IF6 IgG1, IF6
cytotoxic T cell CD8 mouse
monoclonal
M20 Tonsil 1:160 Envision Dako M7103 IgG1k, C8/144B
activated T cell CD25 mouse
monoclonal
M20 Tonsil 1:600 Tyramide signal
amplification
Novocastra NCL-CD25-305 IgG2b, 4C9
B cell CD20 mouse
monoclonal
M20 Tonsil 1:400 Envision Dako M0755 IgG2ak, L26
Plasma cell CD138 mouse
monoclonal
M20 Tonsil 1:1000 Envision Dako M7077 IgG1k, VS38C
NK cell CD56 mouse
monoclonal
M20 Appendix 1:150 Envision Monosan MON9006-1 IgG1
Macrophage CD68 mouse
monoclonal
T16/M20 Tonsil 1:300 Envision Dako M0814 IgG1k, KP1[4]
Classically
activated
macrophage
iNOS mouse
monoclonal
M20 Appendix/colorectal
carcinoma
1:400 Tyramide signal
amplification
BD
biosciences
610328 6, IgG2a
Alternatively
activated
macrophage
Arginase I rabbit
polyclonal
M20 Liver 1:40 Envision Santa Cruz sc-20150 H-52
Neutrophil Neutrophil
elastase
mouse
monoclonal
nil Tonsil 1:100 Envision Dako M0752 IgG1k, NP57
Mast cell Mast cell
tryptase
mouse
monoclonal
M20 Tonsil/Appendix 1:30,000 Envision Dako M7052 IgG1k, AA1
*M = heat induced by microwaving in 10mM citrate buffer, pH 6.0., T = enzymatic digestion performed at 37uC, in 0.2% trypsin, 0.1% calcium chloride solution, pH 7.8.,
numerical values = time for antigen retrieval.
doi:10.1371/journal.pone.0015366.t001
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using the RNeasy mini kit (Qiagen, Crawley, UK, 74104),
incorporating Qiashredder column tissue homogenisation and
on-column DNase digestion. Agilent BioAnalyzerH profiling
assessed yield and quality of the extracted total RNA. 500ng of
total RNA was used to synthesize biotinylated cRNA using the
Oligo-GEArray Reagent kit (Superarray Biosciences, USA, GA-
034). Following quality assessment by Nanodrop spectrophotome-
tryH, this was hybridised to a commercially available targeted
Oligo-GEArrayH gene filter, Human Inflammatory Cytokines and
Receptors (OHS-011, Superarray Bioscience, USA), representing
112 inflammatory cytokine and receptor genes. Array images were
captured using a Fuji LAS1000 cooled CCD camera. Hybridised
arrays from each patient were imaged together. Signal intensity
was analysed using AIDA Image Analyser programme v3.21
(Raytest Isotopenmessgeräte GmBH, Straubenhardt, Germany).
Microarray data was validated by quantitative reverse transcrip-
tase real-time PCR. Reverse transcription was performed using
500ng total RNA and random primers, catalyzed with Super-
scriptTM II reverse transcriptase (concentration 200units/ml)
(Invitrogen, UK, 18064-14). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and beta-2-microglobulin (B2M) were selected
as normaliser genes from the initial microarray filter gene
expression data. All primers were obtained from Superarray
Bioscience (UK distributer; Tebu-Bio, Peterborough, UK). Real-
time PCR reaction for each sample was performed on a Biorad
iCyclerH (Bio-Rad Laboratories, UK) in duplicate, incorporating
RT2 Real-TimeTM SYBR green mastermix (PA-010)(Superarray
Bioscience, USA). A 10 fold serial dilution standard curve was
included for each gene of interest and both normalisers on each
plate. Data was included if the PCR efficiency fell between 80% to
105%. A no template control was included. The PCR cycling
programme (15 minutes, 95uC to activate the Taq polymerase,
followed by 40 cycles of 95uC for 15 seconds, 55uC for 30 seconds
and 72uC for 30 seconds) was followed immediately by a default
melting curve program to 96uC. Sequence verification of PCR
amplicons was performed by either cloning into pGEMH- T easy
vector system (Promega, Southhampton, UK, A1360), incorpo-
rating transformation of JM109 high efficiency competent cells
(Promega, Southhampton, UK, L2001) and the universal M13
primer, or purification of RT-PCR product and sequencing using
custom designed gene specific primers based on reference positions
indicated from RefSeq accession number supplied with Super-
array primer assays.
Statistical methods
Differences in inflammatory cell infiltrate between tissue types
and in relation to adenoma size was assessed using paired t-tests.
One way ANOVA assessed the relationship between inflammatory
infiltrate and degree of dysplasia. One paired T test assessed
macrophage phenotype. Both absolute and relative differences in
function were tested in a one way ANOVA. SAS 9.1.3 for
Windows XP (SAS Institute, Cary, NC, USA) was used for
statistical analyses.
Gene array signal intensities were normalised to background
signal, log-transformed and rescaled to ensure each data point lay
between lowest and highest signal intensity. Data from short and
long exposure images were analysed in combination and a
weighted average generated. ANOVA was conducted with Patient
as blocking variable. Gene expression signals between normal,
adenoma and CRC were compared and greater than 2 fold
difference in expression pattern identified. RT-PCR data was
analysed using a paired t-test, incorporating the 22DD CT (Livak)
method as previously published [12].
Statistical significance was set at p,0.05 throughout.
Ethics
Ethical approval for this study was obtained from Grampian
Ethics Committee. Written informed consent was obtained from
all participants.
Results
Assessment of inflammatory cell phenotype
Patient and adenoma characteristics are shown in Table 2.
Macrophage (p = 0.0002), neutrophil (p = 0.0001), helper T cells
Table 2. Adenoma and patient characteristics.
Adenoma and patient characteristics
Adenomas collected within paired
polyp-normal sample set (n = 64) LGD (n = 40) HGD (n = 40) CaP (n = 40)
Colonic site Left sided* 54 (85%) 35 (88%) 37 (92%) 37 (92%)
Right sided 10 (15%) 5 (12%) 3 (8%) 3 (8%)
Polyp size Small (#1cm) 35 (55%) 11 (27%) 8 (20%) 5 (12%)
Large (.1cm) 29 (45%) 29 (73%) 32 (80%) 35 (88%)
Histological
classification
Tubular adenoma 50 (78%) 32 (80%) 15 (38%) 13 (32%)
Tubulo-villous adenoma 14 (22%) 8 (20%) 25 (62%) 27 (68%)
Degree of dysplasia Low grade 56 (88%) 0 (0%) 0 (0%) 0 (0%)
High grade 2 (3%) 40 (100%) 0 (0%) 0 (0%)
Cancer polyp 6 (9%) 0 (0%) 40 (100%) 40 (100%)
Source CRC screening 64 (100%) 32 (80%) 2 (5%) 5 (12%)
Diagnostic database 0 (0%) 8 (20%) 38 (95%) 35 (88%)
Patient age (years) 63 (53–69) 63 (55–79) 71 (45–92) 67 (38–89)
Gender Male 58% 60% 55% 53%
Female 42% 40% 45% 47%
*distal to splenic flexure.
doi:10.1371/journal.pone.0015366.t002
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(p = 0.004),activated T cells (p = 0.0001) and NK cells (p = 0.04)
were increased in adenomas compared to adjacent normal mucosa
(Table 3 and Figure 1). Infiltration of macrophage, neutrophil and
activated T cells correlated with adenoma size, with correlation
co-efficient of 0.51 (p = 0.0001), 0.27 (p = 0.03) and 0.50 (p =
0.0001), respectively. This represented a mean cell count of 9
(95% CI 6–12) in small polyps compared to 12 (95% CI 6–19) in
large polyps for neutrophil infiltrate (p = 0.0006), 12 (95% CI 9–
14) in small polyps compared to 20 (95% CI 16–25) in large polyps
for macrophage infiltrate (p = 0.003) and 2 (95% CI 1–3) in small
polyps compared to 8 (95% CI 6–11) in large polyps for activated
T cell infiltrate (p = 0.0001). T helper cells did not increase along
with adenoma size (p = 0.23). There was an increase in macro-
phage (p = 0.0001) and neutrophils (p = 0.0001) as the degree of
dysplasia progressed from low grade to high grade and finally to
overt invasive adenocarcinoma (Table 4). There was a statistically
significant increase in T helper cells in cancer polyps compared to
their benign adenomatous counterparts (p = 0.009). There was
no increase in activated T cell infiltration in association with
increasing degree of cell dysplasia (p = 0.06).
Assessment of macrophage phenotype
There were no iNOS positive pro-inflammatory macrophages
in the normal colonic mucosal biopsies. In comparison, within
paired adenomas, these cells were a key feature of the stroma with
84% (61%–93%) of the macrophage population expressing iNOS
(p = 0.001) (Table 5). Arginase I expression within the macrophage
population was not a prominent feature of either the normal
mucosal biopsies or the adenomas. Overall, there appeared to be
more arginase I expressing macrophages within the stroma of the
polyps, when analysed as both the absolute number of arginase I
positive cells and the percentage of arginase I positive cells within
the total macrophage population, and this was statistically
significant with p = 0.001 and p = 0.023, respectively, but the
overall number of positive cells were low (Table 5). 45%, 67% and
34% of the total macrophage population expressed iNOS in the
low grade dysplastic, high grade dysplastic and cancer polyp
groups, respectively. This is compared to 12%, 5% and 13% of
macrophage expressing arginase I. The difference in this pattern of
enzymatic expression favours a pro-inflammatory phenotype. The
relative proportion of iNOS expressing pro-inflammatory cells to
arginase I expressing regulatory cells was greatest in the low grade
dysplastic (p = 0.001) and high grade dysplastic groups (p = 0.001).
The relative proportion of regulatory to pro-inflammatory
macrophage was higher in the cancer polyp group suggesting
that regulatory macrophage are more abundant within areas of
invasive disease.
Profiling of inflammatory gene expression
The average age of the patients was 71 years (range 55–79). Five of
the patients were male. Five of the cancers originated on the left side
of colon. On staging, one was Duke’s A, 4 Dukes B and 2 Dukes C.
CXCL1, CXCL2, CXCL3, CCL20, and IL-8 had increased
expression in the adenoma and adenocarcinoma compared to
normal colonic mucosa. CCL19, CCL21, CCL23, CCL5, were
found to have reduced expression in the adenoma and
adenocarcinoma compared to normal mucosa (Table 6, and
Figure 2). It is clear that the change in expression of all of these
genes occurs in the precancerous adenomatous lesion, early in the
neoplastic process, prior to malignant transformation. Expression
pattern of all of these genes was validated by RT-PCR, normalised
to both housekeeper genes (B2M and GAPDH) (data for GAPDH
shown in Table S1). Identification of the PCR products was
confirmed by sequencing of the PCR amplicons.
Discussion
This study has defined the inflammatory cell phenotype within
the stromal microenvironment of human colorectal pre-malignant
adenomas and identified how this evolves with adenoma
progression to overt invasive disease. In addition, several pro-
inflammatory genes are differentially expressed in pre-malignant
colonic adenomatous polyp compared to adjacent normal mucosa.
All of the 9 differentially expressed genes are linked to inflam-
mation and key cell functions important in tumour biology. IL-8 is
a known potent chemoattractant of neutrophils and macrophages
to areas of inflammatory activity. IL-8 is also mitogenic [13],
angiogenic [14] and, through linked expression of MMP’s,
influences tumour cell motility such that invasion is enhanced
[15]. CCL20 is a chemokine involved in directing lymphoid cell
migration through binding to its receptor CCR6. CCR6 is
significantly up-regulated in both colorectal cancer and associated
liver metastases and data suggests that it plays a role in the
recruitment of CCR6+ tumour cells to the site of distant metastases
[16]. CXCL1 expression is up-regulated in colorectal adenomas
and adenocarcinoma [17], inhibiting apoptosis and inversely
Table 3. Assessment of inflammatory cell phenotype in 65 colonic adenomas and 35 adjacent normal mucosal biopsies (paired T
test).
Inflammatory cell Normal Colon Adenomatous Polyp Mean Difference (95% CI) P-Value
T helper cell 13.19 (11.84) 21.80 (14.67) 8.61 (2.95, 14.27) 0.004
Cytotoxic T cell 6.25 (7.97) 6.00 (8.31) 20.25 (22.66, 2.16) 0.83
B cell 2.78 (6.56) 4.11 (7.31) 1.33 (21.60, 4.27) 0.36
Activated T cell 2.32 (2.67) 7.69 (5.71) 5.53 (3.34, 7.72) ,0.0001
NK cell 0.19 (1.01) 2.11 (5.39) 1.92 (0.11, 3.72) 0.04
Macrophage 10.83 (10.20) 19.63 (10.69) 8.91 (4.50, 13.32) 0.0002
Mast cell 10.00 (5.35) 10.56 (9.63) 0.71 (21.97, 3.40) 0.59
Neutrophil 1.56 (3.22) 14.83 (14.76) 13.28 (8.37, 18.19) ,0.0001
Plasma cell 5.50 (7.19) 6.00 (8.18) 0.50 (22.61, 3.61) 0.75
In this analysis, the maximum infiltrate value was used for the polyp when more than 1 polyp existed.
Numerical data represents mean cell counts (with mean of standard deviation).
doi:10.1371/journal.pone.0015366.t003
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linked to expression of fibulin-1, an extra-cellular matrix protein
implicated in control of tumour cell migration. Wang et al. (2006)
[18] reported that expression of CXCL1 induced by PGE2 was
linked to angiogenesis in colorectal cancer in vitro and in vivo and
thus provided a link between COX-2 up-regulation and
chemokine induced tumour associated endothelial cell migration.
Of interest, is the fact that expression of several chemokines was
down-regulated in adenomas. CCL23 is an immune mediator
involved in the chemotaxis of monocytes but not neutrophils [19].
CCL23 inhibits the release of neutrophils and monocytes from
bone marrow, suggesting that it may be an important mediator in
regulating bone marrow response during immune stimulation
[20]. In addition, CCL23 confers angiogenic properties [21],
mediated through up-regulation of MMP2 gene expression in
endothelial cells [22]. CCL5 drives T cell and monocyte migration
and activation, with increased expression linked to a number of
malignancies [23,24]. CCL5 was not found to be up-regulated in
colorectal cancer compared to adjacent normal mucosa by Baier
and colleagues [25] and this would be in keeping with the present
study. CCL19 and CCL21 are structurally related chemokines
that share the common receptor, CCR7. They play a pivotal role
in the development of secondary lymphoid tissue as seen in animal
models of deficiency [26,27] and are involved in T cell activation
through interaction with dendritic cells within secondary lymphoid
organs. It is difficult to speculate on the biological ramifications of
differential expression of each of these chemokines individually.
However, the dysregulation of these inflammatory cytokine and
chemokine genes in adenomatous polyps compared to adjacent
Table 4. Assessment of inflammatory cell infiltrate in colonic
adenomas in relation to increasing degree of epithelial cell
dysplasia (one way ANOVA).
Inflammatory
cell
Low grade
dysplasia
High grade
dysplasia
Cancer
polyps P value
T helper cell 14.20 (40) 13.80 (40) 21.95 (38) 0.009
Activated T cell 4.95 (40) 5.43 (40) 8.26 (39) 0.06
Macrophage 40.37 (39) 55.89 (40) 82.33 (39) ,0.0001
Neutrophil 8.13 (40) 17.80 (40) 31.44 (39) ,0.0001
Numerical data denotes mean cell counts. () = n.
doi:10.1371/journal.pone.0015366.t004
Figure 1. Inflammatory cell infiltration in colorectal adenomas compared to normal colonic mucosa. Macrophage infiltrate was
increased in polyps (B) compared to adjacent normal mucosa (A). Neutrophil infiltrate was increased in polyps (D) compared to adjacent normal
mucosa (C). CD25+ activated T cells were increased in polyps (F) compared to adjacent normal mucosa (E).
doi:10.1371/journal.pone.0015366.g001
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normal mucosa complements the cellular findings of an active
inflammatory stromal microenvironment and is worthy of further
investigation.
Several gene expression studies have previously been performed
on normal and diseased colonic tissue. In general, a genome wide
approach has been applied to identify genes dysregulated in
malignant tissue that can be targeted in treatment strategies and
for staging [28–30]. In contrast, there are fewer reports of gene
expression studies in pre-malignant colorectal adenomas [31–34].
Each stage of the adenoma-carcinoma sequence may have an
identifying gene signature primarily involving genes related to cell
cycle, cell growth, RNA and protein processing and cell signalling.
Sabates-Bellver et al [35] assessed 32 pedunculated colorectal
adenomas compared to normal mucosa and identified differential
expression of several inflammatory genes in adenomas, corre-
sponding to those identified from our data analysis. Specifically,
CCL19 and CCL5 had reduced expression in polyp lesions. In
addition, IL-8, CXCL1, CXCL2, CXCL3, and CCL20 had higher
levels of expression in the polyps compared to normal, which is in
keeping with the current study.
The gut exerts a continuous low grade ‘physiological’ mucosal
inflammatory activity, in response to continual challenges from
luminal contents, with T helper cell, macrophage, CD8+ T cells,
and plasma cell infiltrates [36,37]. The normal mucosal biopsies in
this study revealed mucosal immunoactivity as expected. The
demonstration that polyps harbour an increased cellular inflam-
matory infiltrate over and above what is expected in ‘‘normal’’
colonic tissue is an important finding. This study has shown that
adenomatous polyps are rich with pro-inflammatory macrophage,
neutrophil and T helper cell infiltration and these are likely to
exert a significant influence on their surrounding microenviron-
ment within the polyp lesion. NK cells were also found to be
increased in polyp compared to normal mucosa. However, the
majority of polyps did not have any evidence of CD56+ NK cell
infiltrate and those that did had an average of only 5 positive cells/
HPF. This only marginally achieved statistical significance
(p = 0.04) and the relevance of this in the biological microenvi-
ronment is debatable and requires further evaluation.
Neutrophils are a source of N- nitrosamines, especially in the
presence of colonic amine producing bacteria, and these are
known to be carcinogenic [38,39]. Coussens et al [40] showed that
neutrophil and macrophage derived MMP-9 enhanced progres-
sion from dysplasia to overt malignancy through paracrine
signalling in a mouse model of squamous skin cancer, with
reduced MMP-9 delaying angiogenesis within dysplastic areas and
reducing the incidence of invasive disease. In addition, inflamma-
tory cells of haemopoetic origin, introduced by bone marrow
transplant, were identified in hyperplastic, dysplastic and neoplas-
tic skin lesions, and produced MMP-9 driven changes associated
with early carcinogenesis. Our previous data showed that MMP-9
is expressed within adenomatous polyps [41]. Recently, Jablonska
and colleagues [42] have demonstrated that endogenous IFNb
inhibits angiogenesis, by inhibiting pro-angiogenic genes within
tumour associated neutrophils, in a transplantable mouse tumour
model. Neutrophil elastase, secreted by neutrophils, is a main
constituent of phagocytic response, degrading proteins within the
local environment such as elastin, collagen and other constituents
of extracellular matrix [43]. Elastase deficient mice have
significantly reduced skin carcinoma load in response to repeated
UV light or chemical exposure [44]. Administration of a specific
Table 5. Assessment of macrophage phenotype in colonic adenomas (n = 42) and adjacent normal mucosa (n = 25).
() = 25th and 75th centiles.
Normal colon Adenomatous polyp P value
Median number of iNOS+ cells 0 (0–3) 11 (6–18) 0.001
% iNOS+ cells/total CD68+ cells 0% (0%–43%) 84% (61%–93%) 0.001
Median number of arginase I+ cells 0 (0–1) 1 (0–2) 0.001
% arginase I+ cells/total CD68+ cells 0% (0%–10%) 6% (0%–25%) 0.023
doi:10.1371/journal.pone.0015366.t005
Table 6. Differential expression of inflammatory genes in colorectal neoplastic progression.
Gene Normal(N) Adenoma(Ad) CRC P value N.vs.Ad P value N.vs.CRC P value Ad.vs.CRC
CCL20 2.47 3.97 3.65 0.014 0.044 0.537
CXCL1 1.60 3.52 3.31 0.001 0.001 0.520
CXCL2 1.35 3.10 3.16 0.003 0.002 0.910
CXCL3 0.77 1.76 1.88 0.009 0.004 0.712
IL-8 1.63 2.84 3.42 0.01 0.001 0.173
CCL5 3.61 2.40 2.59 0.007 0.017 0.660
CCL19 2.73 1.57 1.59 0.004 0.004 0.944
CCL21 2.98 1.87 2.23 0.007 0.052 0.285
CCL23 2.02 0.96 0.91 0.001 0.001 0.831
Gene expression in normal colonic mucosa vs. pre-malignant adenomatous polyp (Ad) vs. invasive adenocarcinoma (CRC). Bold denotes genes with increased
expression in neoplastic tissue compared to normal mucosa, and italics denotes genes with reduced expression in neoplastic tissue compared to normal mucosa.
doi:10.1371/journal.pone.0015366.t006
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neutrophil elastase inhibitor suppressed the proliferation and
motility of a pancreatic cancer cell line [45], as well as squamous
and adenocarcinoma cell lines of lung malignancy [46]. The
underlying mechanism is unclear. Degradation of protein trans-
cription factors may disrupt regulatory proteins of gene expression
[44]. Reactive oxygen species derived from polymorphs can
indirectly affect gene expression by, for example, modulating
enzyme activity and promoting changes in transcription factor
binding capacity. Neutrophil activation has been implicated in cell
cycle G2/M arrest, dependent on expression of p53 and p21, and
associated with DNA damage checkpoint mechanisms, in an in
vitro co-culture model mimicking colitis [47].
Pro-inflammatory macrophages are a central and potent
constituent of innate immunity. Within our cancer polyp group,
the macrophage population appears to change with a reduced
proportion of iNOS expressing classically activated cells. Macro-
phages are well recognised at sites of malignancy. Tumour
associated macrophage have poor antigen presenting capabilities
with a limited anti-tumour response. This reduced tumoricidal
capacity has been linked to reduced iNOS expression [48] and
would be in keeping with the current data.
There is pharmacological evidence for the role of inflammation in
the development of colorectal neoplasia. Several large randomised
controlled trials have shown that regular aspirin use can reduce the
risk of CRC and adenoma development by up to 50% [49–52]. The
use of aspirin or NSAIDs in our study population is unknown.
This study has defined the stromal microenvironment of pre-
malignant colorectal adenomas and identified key inflammato-
ry components involved in adenoma progression to invasive
malignancy. It is clear from our data that a phenotypic and
genotypic ‘switch’ occurs early in the adenoma-carcinoma
sequence, with expression of inflammatory cytokines and
chemokines dysregulated in the transition from normal mucosa
to adenomatous polyp, rather than at the polyp to invasive
disease transition. This data increases the understanding of the
environmental influences within the adenoma in relation to
disease progression and may have identified potential mecha-
nistic pathways in the initiation and promotion of early
colorectal carcinogenesis. Ultimately, this may identify pheno-
typic markers within adenomas which determine malignant
potential.
Supporting Information
Table S1 RT-PCR validation of gene expression in normal
colonic mucosa, adenomatous polyp and adenocarcinoma (CRC),
normalised to expression of GAPDH and B2M. P value generated
from 2 tailed t-test statistical analysis. Bold denotes genes with
increased expression in neoplastic tissue compared to normal
mucosa, and italics denotes genes with reduced expression in
neoplastic tissue compared to normal mucosa.
(DOC)
Figure 2. Signal intensity of targeted microarray. Signal intensity of targeted microarray with gene expression in 5 genes significantly up-
regulated in adenoma and CRC compared to normal (A) and 4 genes significantly down-regulated in adenoma and CRC compared to adjacent normal
mucosa (B) (p values noted in Table 6).
doi:10.1371/journal.pone.0015366.g002
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